The content on this site is intended for healthcare professionals only
Dr Conroy presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a phase III randomised trial in which patients with surgically resected pancreatic cancer were treated with mFOLFIRINOX.
Compared to those receiving the current standard of care, gemcitabine, trial participants had a median disease free survival of 21.6months v 12.8months, and a median overall survival of 54.4 months v 35 months.
For more on these findings, watch his interview with ecancer, or read news coverage here.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
Latest in immunological technologies that can treat, control, and prevent cancer
OncoAlert Round Up for August 4th - 10th, 2023
